Condensed Consolidated Statements of Shareholders' Equity - USD ($) $ in Thousands	Total	Cumulative Effect, Period of Adoption, Adjustment	Common Shares	Additional  Paid-In Capital	Accumulated Deficit	Accumulated Deficit Cumulative Effect, Period of Adoption, Adjustment	Accumulated Other Comprehensive Loss
Beginning balance (in shares) at Mar. 31, 2020			280,853,000
Beginning balance at Mar. 31, 2020	$ 965,704	$ 306	$ 281	$ 1,573,347	$ (589,819)	$ 306	$ (18,105)
Increase (Decrease) in Partners' Capital [Roll Forward]
Foreign currency translation	(9,920)						(9,920)
Restricted stock units vested (in shares)			1,035,000
Restricted stock awards forfeited (in shares)			(103,000)
Issuance of common stock related to employee stock purchase plan (in shares)			331,000
Issuance of common stock related to employee stock purchase plan	9,195			9,195
Exercise of stock options (in shares)			427,000
Exercise of stock options	6,849			6,849
Share-based compensation	43,091			43,091
Equity repurchases	$ (36)			(36)
Accounting Standards Update [Extensible List]	Accounting Standards Update 2016-02 [Member]
Net income	$ 48,760				48,760
Ending balance (in shares) at Dec. 31, 2020			282,543,000
Ending balance at Dec. 31, 2020	1,063,949		$ 281	1,632,446	(540,753)		(28,025)
Beginning balance (in shares) at Sep. 30, 2020			282,024,000
Beginning balance at Sep. 30, 2020	1,027,119		$ 281	1,609,246	(559,169)		(23,239)
Increase (Decrease) in Partners' Capital [Roll Forward]
Foreign currency translation	(4,786)						(4,786)
Restricted stock units vested (in shares)			229,000
Restricted stock awards forfeited (in shares)			(7,000)
Issuance of common stock related to employee stock purchase plan (in shares)			172,000
Issuance of common stock related to employee stock purchase plan	5,603			5,603
Exercise of stock options (in shares)			125,000
Exercise of stock options	2,020			2,020
Share-based compensation	15,588			15,588
Equity repurchases	(11)			(11)
Net income	18,416				18,416
Ending balance (in shares) at Dec. 31, 2020			282,543,000
Ending balance at Dec. 31, 2020	$ 1,063,949		$ 281	1,632,446	(540,753)		(28,025)
Beginning balance (in shares) at Mar. 31, 2021	283,130,238		283,130,000
Beginning balance at Mar. 31, 2021	$ 1,113,601		$ 283	1,653,328	(513,799)		(26,211)
Increase (Decrease) in Partners' Capital [Roll Forward]
Foreign currency translation	1,428						1,428
Restricted stock units vested (in shares)			1,049,000
Restricted stock units vested	0		$ 1	(1)
Restricted stock awards forfeited (in shares)			(19,000)
Issuance of common stock related to employee stock purchase plan (in shares)			372,000
Issuance of common stock related to employee stock purchase plan	$ 13,914		$ 1	13,913
Exercise of stock options (in shares)	1,170,000		1,170,000
Exercise of stock options	$ 23,651		$ 1	23,650
Share-based compensation	71,950			71,950
Equity repurchases	(51)			(51)
Net income	$ 51,522				51,522
Ending balance (in shares) at Dec. 31, 2021	285,701,744		285,702,000
Ending balance at Dec. 31, 2021	$ 1,276,015		$ 286	1,762,789	(462,277)		(24,783)
Beginning balance (in shares) at Sep. 30, 2021			285,025,000
Beginning balance at Sep. 30, 2021	1,221,002		$ 285	1,723,056	(476,864)		(25,475)
Increase (Decrease) in Partners' Capital [Roll Forward]
Foreign currency translation	692						692
Restricted stock units vested (in shares)			252,000
Issuance of common stock related to employee stock purchase plan (in shares)			168,000
Issuance of common stock related to employee stock purchase plan	7,321		$ 1	7,320
Exercise of stock options (in shares)			257,000
Exercise of stock options	5,311			5,311
Share-based compensation	27,123			27,123
Equity repurchases	(21)			(21)
Net income	$ 14,587				14,587
Ending balance (in shares) at Dec. 31, 2021	285,701,744		285,702,000
Ending balance at Dec. 31, 2021	$ 1,276,015		$ 286	$ 1,762,789	$ (462,277)		$ (24,783)